Xinkai Pharmaceutical

Shanghai Xinkai Pharmaceutical, widely known as Cinkate, is a biopharmaceutical company specializing in the development and commercialization of innovative small molecule drugs for autoimmune diseases, oncology, and chronic disease management. Founded in 1994 with operations in both the United States and China, the company gained prominence by launching Airohua (leflunomide), the first innovative drug for rheumatoid arthritis in the Chinese market. Xinkai maintains a robust commercial presence through strategic partnerships, such as its collaboration with UCB for the distribution of Cimzia (certolizumab pegol) in China. Beyond traditional drug development, the company has pioneered the Smart System of Disease Management (SSDM), a leading digital health platform that facilitates real-time physician-patient interaction and chronic disease monitoring. Its current R&D pipeline focuses on novel triptolide analogs and advanced treatments for metabolic and inflammatory conditions.